Periotherapia
Osaka
About Periotherapia
Periotherapia is a Drug discovery business with triple negative breast cancer as the first indication. Periotherapia aims to selectively inhibit only ASV that is involved in pathogenesis without inhibiting physiological ASV in chronic diseases such as cancer, heart failure, arteriosclerosis, renal failure, and diabetic retinopathy. is.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $5.4M
- Funding stage: Early Stage Venture
- Last round: Series B (Sep 2020)
- Website: periotherapia.co.jp
- Phone: +81 06-6210-8409
Industries & Categories
Alternative Medicine, Personal Health, Therapeutics
Canonical: https://fsome.com/organization/periotherapia-53872 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.